Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 41: Hormone replacement therapy is contraindicated in which of the following conditions?

A. Atherosclerosis
B. Thromboembolism (Correct Answer)
C. Osteoporosis
D. Gall stones

Explanation: **Explanation:** **1. Why Thromboembolism is the Correct Answer:** Hormone Replacement Therapy (HRT), specifically the estrogen component, is associated with a prothrombotic state. Estrogen increases the hepatic synthesis of clotting factors (II, VII, IX, X) and decreases anticoagulants like Antithrombin III and Protein S. This significantly elevates the risk of **Venous Thromboembolism (VTE)**, including Deep Vein Thrombosis (DVT) and Pulmonary Embolism. Therefore, a history of or active thromboembolic disease is an **absolute contraindication** for HRT. **2. Analysis of Incorrect Options:** * **A. Atherosclerosis:** While HRT is generally not started in women with established coronary artery disease (CAD), it is not an absolute contraindication in the same way as active VTE. According to the "Timing Hypothesis," starting HRT early in menopause may actually be cardioprotective. * **C. Osteoporosis:** This is an **indication**, not a contraindication. HRT is highly effective in preventing bone loss and reducing the risk of osteoporotic fractures in postmenopausal women. * **D. Gallstones:** While HRT can increase the risk of cholelithiasis (by increasing cholesterol saturation in bile), it is considered a **relative contraindication**. It does not carry the same immediate life-threatening risk as thromboembolism. **3. High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications for HRT:** Undiagnosed abnormal vaginal bleeding, known or suspected Estrogen-dependent tumors (Breast/Endometrial CA), active/recent Thromboembolism (DVT/PE), and active Liver disease. * **Route Matters:** Transdermal estrogen has a lower risk of VTE compared to oral estrogen because it bypasses the first-pass hepatic metabolism. * **The "Gold Standard" Indication:** The primary indication for HRT is the relief of moderate-to-severe vasomotor symptoms (hot flashes, night sweats).

Question 42: Which of the following is NOT true about hot flushes?

A. Hot flushes typically last for 1 to 5 minutes.
B. Skin temperature rises due to peripheral vasodilation.
C. Systolic blood pressure drops during a hot flush. (Correct Answer)
D. Heart rate rises during a hot flush.

Explanation: **Explanation:** Hot flushes (vasomotor symptoms) are the most common symptom of the perimenopause, caused by a narrowing of the thermoregulatory window in the hypothalamus due to estrogen withdrawal. **Why Option C is the correct answer:** During a hot flush, there is a transient **increase** in both heart rate and **systolic blood pressure**, not a drop. This is due to a surge in sympathetic nervous system activity. While peripheral vasodilation occurs to dissipate heat, the compensatory cardiac output increase typically leads to a slight rise in systolic pressure. **Analysis of Incorrect Options:** * **Option A:** Hot flushes are transient episodes. They typically last between **1 to 5 minutes**, though the frequency and intensity vary significantly among women. * **Option B:** The core physiological event is **peripheral vasodilation**, particularly in the face, neck, and chest. This leads to a measurable **rise in skin temperature** (often by 1–7°C) and visible flushing. * **Option C:** As mentioned, the sympathetic surge causes a **rise in heart rate** (tachycardia), often accompanied by palpitations. **NEET-PG High-Yield Pearls:** * **Most common symptom of menopause:** Hot flushes (75% of women). * **First sign of menopause:** Shortening of the follicular phase (decreased cycle length). * **Gold Standard Treatment:** Hormone Replacement Therapy (HRT). * **Non-hormonal DOC:** SSRIs/SNRIs (e.g., Paroxetine, Venlafaxine) or Gabapentin. * **Mechanism:** Estrogen deficiency leads to low endorphin levels, which increases GnRH pulses and disrupts the hypothalamic "thermostat."

Question 43: All of the following parameters increase in post-menopausal women except?

A. Plasminogen activator inhibitor-1
B. Factor VII
C. Fibrinogen
D. Antithrombin (Correct Answer)

Explanation: **Explanation:** The post-menopausal state is characterized by a significant decline in estrogen levels, which leads to a **pro-thrombotic (hypercoagulable) state**. This shift increases the risk of cardiovascular diseases and venous thromboembolism (VTE) in older women. **1. Why Antithrombin is the Correct Answer:** Antithrombin (specifically Antithrombin III) is a natural **anticoagulant**. In the post-menopausal period, the levels of natural anticoagulants like Antithrombin III and Protein S typically **decrease** or remain unchanged, rather than increase. A decrease in these protective factors contributes to the overall increased risk of thrombosis. **2. Analysis of Incorrect Options (Factors that Increase):** * **Plasminogen Activator Inhibitor-1 (PAI-1):** Levels increase after menopause. PAI-1 inhibits fibrinolysis (the breakdown of clots), thereby promoting a pro-thrombotic environment. * **Factor VII & Fibrinogen:** These are pro-coagulant factors. Estrogen deficiency leads to an increase in the synthesis of several clotting factors, including Factor VII and Fibrinogen, which enhances blood viscosity and clot formation. **High-Yield Clinical Pearls for NEET-PG:** * **Lipid Profile Changes:** Post-menopause, there is an increase in LDL, VLDL, and Triglycerides, and a **decrease in HDL**, leading to an increased risk of atherosclerosis. * **Hormone Replacement Therapy (HRT) & Coagulation:** Oral HRT can further increase the risk of VTE by increasing Factor VII, X, and fragments of prothrombin, while decreasing Antithrombin III. * **Most Sensitive Marker for Menopause:** Elevated **FSH** (>40 IU/L) is the gold standard biochemical marker. * **Cardiovascular Risk:** Before menopause, women have a lower risk of MI than men due to the protective effects of estrogen; this advantage is lost post-menopause.

Question 44: A patient is at risk of estrogen-dependent carcinoma, and thus estrogen is contraindicated. To prevent vasomotor symptoms, which drug is given?

A. Tamoxifen
B. Conjugated estrogen
C. Clonidine (Correct Answer)
D. Yombinine

Explanation: **Explanation:** In patients where estrogen is contraindicated (e.g., history of breast cancer, endometrial cancer, or thromboembolism), non-hormonal alternatives are required to manage vasomotor symptoms (hot flashes). **Why Clonidine is correct:** Clonidine is a centrally acting **alpha-2 adrenergic agonist**. Hot flashes are thought to be triggered by a narrowing of the thermoregulatory zone in the hypothalamus, mediated by increased noradrenergic activity. Clonidine reduces central sympathetic outflow, thereby stabilizing the thermoregulatory center and reducing the frequency and severity of hot flashes. **Analysis of Incorrect Options:** * **Tamoxifen (Option A):** This is a Selective Estrogen Receptor Modulator (SERM). While it is used in breast cancer treatment, it actually **exacerbates** vasomotor symptoms and is a common cause of hot flashes. * **Conjugated Estrogen (Option B):** This is the gold standard for menopausal symptoms but is strictly **contraindicated** in patients with estrogen-dependent carcinomas. * **Yohimbine (Option D):** This is an alpha-2 antagonist (the opposite of Clonidine). It increases sympathetic activity and would likely worsen vasomotor instability. **High-Yield Clinical Pearls for NEET-PG:** * **First-line non-hormonal treatment:** SSRIs (e.g., Paroxetine) or SNRIs (e.g., Venlafaxine) are now often preferred over Clonidine due to a better side-effect profile. * **Gabapentin:** Another effective non-hormonal option that improves sleep and reduces hot flashes. * **Tibolone:** A synthetic steroid with estrogenic, progestogenic, and androgenic properties; however, it is also generally avoided in active estrogen-dependent cancers. * **Fezolinetant:** A newer NK3 receptor antagonist specifically approved for moderate-to-severe vasomotor symptoms.

Question 45: Which of the following laboratory findings is diagnostic of menopause?

A. Serum FSH > 40 mIU/mL (Correct Answer)
B. Serum LH > 20 mIU/mL
C. Serum FSH < 40 mIU/mL
D. Serum estradiol < 30 pg/mL

Explanation: **Explanation:** **1. Why Option A is correct:** Menopause is clinically defined as the permanent cessation of menstruation for 12 consecutive months due to the loss of ovarian follicular activity. As the ovarian reserve depletes, there is a significant decrease in **Inhibin B** and **Estradiol**. This loss of negative feedback on the pituitary gland leads to a compensatory rise in Gonadotropins. A **Serum FSH level > 40 mIU/mL** (measured on two occasions, 4–6 weeks apart) is considered the gold standard biochemical marker for confirming menopause. **2. Why other options are incorrect:** * **Option B:** While LH also increases during menopause, it is less reliable than FSH. LH levels typically rise to > 20–30 mIU/mL, but FSH is the primary diagnostic marker due to its longer half-life and more consistent elevation. * **Option C:** FSH levels < 40 mIU/mL are seen in the perimenopausal transition or premenopausal state; they do not confirm the permanent cessation of ovarian function. * **Option D:** While Serum Estradiol levels do drop significantly in menopause (typically < 20–30 pg/mL), estradiol levels fluctuate wildly during the perimenopausal period. Therefore, low estradiol alone is not diagnostic without the corresponding high FSH. **Clinical Pearls for NEET-PG:** * **Earliest biochemical marker** of declining ovarian reserve: **Decreased Inhibin B**. * **Most sensitive marker** for ovarian reserve: **Anti-Müllerian Hormone (AMH)** (levels decrease before FSH rises). * **FSH/LH Ratio:** In menopause, the FSH/LH ratio becomes **> 1**. * **Predominant Estrogen:** In menopause, **Estrone (E1)** (produced via peripheral conversion of androstenedione in adipose tissue) replaces Estradiol (E2) as the dominant estrogen.

Question 46: What happens to Antimullerian hormone levels during menopausal transition?

A. Remain constant
B. Decrease (Correct Answer)
C. Increase
D. Varies

Explanation: **Explanation:** **1. Why the correct answer is right:** Anti-Müllerian Hormone (AMH) is produced by the granulosa cells of pre-antral and small antral follicles. It serves as a direct biochemical marker of the **ovarian reserve**. As a woman approaches the menopausal transition, the primordial follicle pool undergoes accelerated depletion. With fewer follicles remaining, the production of AMH significantly **decreases**. AMH is often the first marker to decline, often becoming undetectable approximately five years before the final menstrual period (FMP), making it a highly sensitive indicator of ovarian aging. **2. Why other options are wrong:** * **A & C (Remain constant/Increase):** These are physiologically incorrect. Since AMH is tied to the follicle count, it cannot stay constant or increase as the ovary undergoes senescence and follicle exhaustion. * **D (Varies):** Unlike FSH and Estradiol, which fluctuate significantly during the perimenopausal period (the "climatric"), AMH levels show minimal intra-cycle variation. Its decline is steady and progressive, not erratic. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Marker:** AMH is the earliest and most sensitive biochemical marker for the decline in ovarian reserve (declines before FSH rises). * **Cycle Independence:** AMH levels are relatively constant throughout the menstrual cycle; therefore, testing can be done on **any day** of the cycle. * **PCOS Correlation:** Conversely, AMH levels are **increased** in Polycystic Ovary Syndrome (PCOS) due to the high number of small antral follicles. * **Hormonal Profile in Menopause:** * **Decreased:** AMH, Inhibin B, Estradiol. * **Increased:** FSH (most diagnostic), LH.

Question 47: A 56-year-old woman presents with hot flushes, irritability, joint pains, and insomnia. What is the most appropriate treatment?

A. Hysterectomy
B. Calcium and vitamin supplementation
C. Combined estrogen, progesterone preparations (Correct Answer)
D. Bisphosphonates

Explanation: **Explanation:** The patient is presenting with classic **vasomotor symptoms** (hot flushes) and psychological symptoms (irritability, insomnia) associated with **menopause**. **1. Why Option C is Correct:** The gold standard treatment for moderate-to-severe menopausal vasomotor symptoms is **Hormone Replacement Therapy (HRT)**. Estrogen is the most effective agent for relieving hot flushes. Since the patient is 56 years old and there is no mention of a prior hysterectomy, she is assumed to have an intact uterus. In women with a uterus, **combined estrogen and progesterone** must be given. Progesterone is added solely to prevent estrogen-induced endometrial hyperplasia and the subsequent risk of endometrial carcinoma. **2. Why Other Options are Incorrect:** * **Option A (Hysterectomy):** This is a surgical intervention for structural pathology (like fibroids or malignancy) and has no role in treating systemic hormonal withdrawal symptoms. * **Option B (Calcium and Vitamin D):** While important for bone health in postmenopausal women, these supplements do not treat vasomotor symptoms or irritability. * **Option D (Bisphosphonates):** These are used to treat osteoporosis by inhibiting osteoclast activity. They do not address the hormonal deficiency causing hot flushes. **Clinical Pearls for NEET-PG:** * **Indication:** The primary indication for HRT is the relief of vasomotor symptoms (not the prevention of CHD). * **Route:** Transdermal estrogen is preferred in women with hypertension, smoking, or risk of VTE (bypasses first-pass metabolism). * **Contraindications:** Undiagnosed vaginal bleeding, history of breast cancer, active VTE, or chronic liver disease. * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Question 48: Regarding vasomotor symptoms seen with menopause, all are true except?

A. Most common symptom of menopause.
B. Fall in circulating oestrogen levels disrupts the body's thermostat.
C. Hot flush affects typically trunk and limbs. (Correct Answer)
D. 70 percent of women experience vasomotor symptoms at menopause.

Explanation: **Explanation:** Vasomotor symptoms (VMS), primarily manifesting as **hot flushes**, are the hallmark of the perimenopausal transition. **Why Option C is the Correct Answer (The False Statement):** A hot flush typically begins as a sudden sensation of intense heat in the **face, neck, and upper chest (the "blush area")**, often accompanied by profuse sweating and palpitations. It does **not** typically involve the limbs. The sensation is caused by peripheral vasodilation to dissipate heat, followed by a compensatory drop in core body temperature. **Analysis of Other Options:** * **Option A:** VMS is indeed the **most common** and earliest symptom of menopause, affecting the majority of women. * **Option B:** The pathophysiology involves a "narrowing of the thermoregulatory window" in the hypothalamus. The withdrawal of estrogen leads to a decrease in endorphins and an increase in norepinephrine and serotonin, which disrupts the body's thermostat. * **Option D:** Approximately **70-80%** of women experience these symptoms during the menopausal transition, though the severity and duration vary significantly. **High-Yield NEET-PG Pearls:** * **Duration:** Hot flushes usually last for 1–5 minutes. While they typically subside within 1–2 years, about 10–15% of women may experience them for over 10 years. * **Night Sweats:** When VMS occurs during sleep, it is termed "night sweats," which often leads to insomnia and "brain fog." * **Treatment Gold Standard:** **Hormone Replacement Therapy (HRT)** is the most effective treatment for VMS. * **Non-Hormonal Alternatives:** SSRIs (Paroxetine), SNRIs (Venlafaxine), and Gabapentin are used for patients where HRT is contraindicated (e.g., history of breast cancer).

Question 49: Which of the following is NOT a potential risk associated with hormone replacement therapy in post-menopausal women?

A. Venous thromboembolism
B. Endometrial cancer
C. Breast cancer
D. Colon cancer (Correct Answer)

Explanation: **Explanation:** The correct answer is **Colon cancer** because Hormone Replacement Therapy (HRT) is actually associated with a **decreased risk** of colorectal cancer, rather than being a risk factor. Large-scale studies, including the Women's Health Initiative (WHI), demonstrated that combined estrogen and progestogen therapy significantly reduces the incidence of colon cancer in post-menopausal women. **Analysis of Options:** * **Venous Thromboembolism (VTE):** Oral HRT increases the risk of VTE (deep vein thrombosis and pulmonary embolism) by increasing the hepatic synthesis of clotting factors and decreasing antithrombin III levels. * **Endometrial Cancer:** Unopposed estrogen therapy (estrogen without progestogen) leads to endometrial hyperplasia and a significantly increased risk of endometrial carcinoma. This is why progestogens are always added for women with an intact uterus. * **Breast Cancer:** Long-term use (typically >5 years) of combined HRT (Estrogen + Progestogen) is associated with an increased risk of breast cancer. Interestingly, estrogen-only therapy (in hysterectomized women) shows a much lower or even negligible risk compared to combined therapy. **High-Yield Clinical Pearls for NEET-PG:** 1. **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy. 2. **Osteoporosis:** HRT is highly effective in preventing post-menopausal bone loss and fractures, though it is no longer the first-line treatment for osteoporosis alone. 3. **Lipid Profile:** Oral estrogen improves the lipid profile by increasing HDL and decreasing LDL, but it also increases triglycerides. 4. **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Question 50: Which of the following is NOT true about the menopausal transition?

A. Increase in FSH
B. Decrease in estrogen
C. Decrease in AMH
D. Increase in inhibin B (Correct Answer)

Explanation: **Explanation:** The menopausal transition is characterized by the depletion of the ovarian follicle pool. To understand the hormonal changes, one must remember the feedback loop between the ovaries and the pituitary gland. **Why Option D is the Correct Answer:** Inhibin B is produced by the granulosa cells of the developing antral follicles. As the number of viable follicles declines during the perimenopausal period, the production of **Inhibin B decreases**. Inhibin B normally exerts negative feedback on the anterior pituitary to suppress FSH. Therefore, a **decrease** (not an increase) in Inhibin B is one of the earliest markers of reproductive aging. **Analysis of Incorrect Options:** * **A. Increase in FSH:** This is the hallmark of menopause. As Inhibin B and Estrogen levels fall, the negative feedback is removed, leading to a compensatory rise in FSH (typically >40 IU/L in menopause). * **B. Decrease in Estrogen:** With the exhaustion of follicles, the primary source of estradiol ($E_2$) disappears. While peripheral conversion of androgens to estrone ($E_1$) continues in adipose tissue, overall estrogen levels significantly decline. * **C. Decrease in AMH:** Anti-Müllerian Hormone (AMH) is produced by pre-antral and small antral follicles. It is the most sensitive marker of ovarian reserve and begins to decline years before the actual menopause. **NEET-PG High-Yield Pearls:** 1. **Earliest hormonal change:** Decrease in Inhibin B. 2. **Earliest clinical sign:** Shortening of the follicular phase (leading to shorter menstrual cycles). 3. **Most sensitive marker of ovarian reserve:** AMH (levels <1 ng/mL indicate low reserve). 4. **Diagnostic hormone for menopause:** FSH (measured on Day 2/3 of the cycle; >40 IU/L is diagnostic). 5. **Predominant Estrogen post-menopause:** Estrone ($E_1$), converted in peripheral fat.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?